Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02385669
Title A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Craig L Slingluff, Jr
Indications

melanoma

Therapies

6MHP vaccine

Ipilimumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.